Giuseppe Del Giudice

Summary

Affiliation: Chiron SpA
Country: Italy

Publications

  1. ncbi Vaccination strategies. An overview
    Giuseppe Del Giudice
    IRIS Research Center, Chiron SpA, Via Fiorentina 1, I 53100 Siena, Italy
    Vaccine 21:S83-8. 2003
  2. ncbi The design of vaccines against Helicobacter pylori and their development
    G Del Giudice
    IRIS Research Center, Chiron SpA, Via Fiorentina 1, Siena, 53100 Italy
    Annu Rev Immunol 19:523-63. 2001
  3. ncbi Towards the development of vaccines against Helicobacter pylori: status and issues
    G Del Giudice
    IRIS Research Center, Chiron SpA, Siena, Italy
    Curr Opin Investig Drugs 2:40-4. 2001
  4. ncbi Helivax Antex Biologics
    G D Giudice
    IRIS Research Center, Chiron SpA, Siena, Italy
    Curr Opin Investig Drugs 2:896-9. 2001
  5. ncbi Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
    Grazia Galli
    Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena 53100, Italy
    Proc Natl Acad Sci U S A 106:3877-82. 2009
  6. ncbi Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines
    Samuele Peppoloni
    IRIS Research Center, Department of Hygiene, Microbiology and Biostatistical Sciences, University of Modena and Reggio Emilia, Italy
    Expert Rev Vaccines 2:285-93. 2003
  7. ncbi Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein
    Karin Baraldo
    Research Center, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Infect Immun 73:5835-41. 2005
  8. ncbi Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice
    Andreas Wack
    Novartis Vaccines, Via Fiorentina 1, Siena, Italy
    Vaccine 26:552-61. 2008
  9. ncbi One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies
    Elisa Faenzi
    Research Development, Novartis Vaccines and Diagnostics Srl, Siena, Italy
    Vaccine 30:4086-94. 2012
  10. ncbi An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
    Giuseppe Del Giudice
    Chiron Vaccines, Research Center and Clinical Research, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 24:3063-5. 2006

Collaborators

Detail Information

Publications32

  1. ncbi Vaccination strategies. An overview
    Giuseppe Del Giudice
    IRIS Research Center, Chiron SpA, Via Fiorentina 1, I 53100 Siena, Italy
    Vaccine 21:S83-8. 2003
    ....
  2. ncbi The design of vaccines against Helicobacter pylori and their development
    G Del Giudice
    IRIS Research Center, Chiron SpA, Via Fiorentina 1, Siena, 53100 Italy
    Annu Rev Immunol 19:523-63. 2001
    ..pylori. Several trials are foreseen in humans, and expectations are that most of the questions being asked now on the host-microbe interactions will be answered...
  3. ncbi Towards the development of vaccines against Helicobacter pylori: status and issues
    G Del Giudice
    IRIS Research Center, Chiron SpA, Siena, Italy
    Curr Opin Investig Drugs 2:40-4. 2001
    ..These studies will tell whether vaccination against H. pylori is feasible in man, and will offer the great opportunity to understand better the relationship between this ancient bacterium and humans...
  4. ncbi Helivax Antex Biologics
    G D Giudice
    IRIS Research Center, Chiron SpA, Siena, Italy
    Curr Opin Investig Drugs 2:896-9. 2001
    ..The vaccine was generally well-tolerated and it generated an immune response in both infected and non-infected individuals [312681]...
  5. ncbi Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
    Grazia Galli
    Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena 53100, Italy
    Proc Natl Acad Sci U S A 106:3877-82. 2009
    ..We suggest that CD4(+) T cell priming might be used as an early predictor of the immunogenicity of prepandemic vaccines...
  6. ncbi Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines
    Samuele Peppoloni
    IRIS Research Center, Department of Hygiene, Microbiology and Biostatistical Sciences, University of Modena and Reggio Emilia, Italy
    Expert Rev Vaccines 2:285-93. 2003
    ..The fully nontoxic LTK63 mutant has now been successfully tested in human volunteers with a trivalent subunit influenza vaccine...
  7. ncbi Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein
    Karin Baraldo
    Research Center, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Infect Immun 73:5835-41. 2005
    ..Taken together, these data show that the N19 polyepitope represents a strong and valid option for the generation of improved or new combined glycoconjugate vaccines...
  8. ncbi Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice
    Andreas Wack
    Novartis Vaccines, Via Fiorentina 1, Siena, Italy
    Vaccine 26:552-61. 2008
    ..These observations have significant implications for the development of new and improved flu vaccines against pandemic and inter-pandemic influenza virus strains...
  9. ncbi One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies
    Elisa Faenzi
    Research Development, Novartis Vaccines and Diagnostics Srl, Siena, Italy
    Vaccine 30:4086-94. 2012
    ..These data shed light on the different components of the immune response to the 2009 H1N1 pandemic influenza vaccination and may have implications in the design of vaccination strategies against future influenza pandemics...
  10. ncbi An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
    Giuseppe Del Giudice
    Chiron Vaccines, Research Center and Clinical Research, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 24:3063-5. 2006
    ..We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine...
  11. ncbi Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene
    Giuseppe Del Giudice
    Research Center, Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Clin Vaccine Immunol 13:1010-3. 2006
    ..In conclusion, antisqualene antibodies are not increased by immunization with vaccines with the MF59 adjuvant. These data extend the safety profile of the MF59 emulsion adjuvant...
  12. ncbi Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus
    Francesca Buricchi
    Research, Novartis Vaccines and Diagnostics, Siena, Italy
    Eur J Immunol 43:641-8. 2013
    ..This may have implications on vaccination strategies aimed at counteracting future influenza pandemics...
  13. ncbi Sortase A confers protection against Streptococcus pneumoniae in mice
    Claudia Gianfaldoni
    Novartis Vaccines and Diagnostics Srl, Research Center, Siena, Italy
    Infect Immun 77:2957-61. 2009
    ..Taken together, our results suggest that SrtA is a good candidate for inclusion in a multicomponent, protein-based, pneumococcal vaccine...
  14. ncbi Generating memory with vaccination
    Flora Castellino
    Research Center, Novartis Vaccines, Siena, Italy
    Eur J Immunol 39:2100-5. 2009
    ..We will also discuss how extending clinical investigation to events occurring early after vaccination can help identify early predictive markers of protective memory and thus contribute to faster development of better and safer vaccines...
  15. ncbi Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses
    Isabella Alberini
    Novartis Vaccines, Siena, Italy
    Vaccine 27:5998-6003. 2009
    ..Overall, the PPN assay represents a valid alternative to conventional serological methods for the evaluation of H5N1 vaccine immunogenicity...
  16. ncbi N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines
    Karin Baraldo
    Research Center, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Infect Immun 72:4884-7. 2004
    ..N19-based conjugates are superior to CRM-based conjugates to induce protective immune responses to MenC conjugates...
  17. ncbi Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system
    Barbara C Baudner
    Research Center, Chiron Srl, Siena, Italy
    J Infect Dis 189:828-32. 2004
    ..These data could affect the design of efficacious mucosal vaccines and their safety...
  18. ncbi Red wine and green tea reduce H pylori- or VacA-induced gastritis in a mouse model
    Paolo Ruggiero
    Novartis Vaccines and Diagnostics s r l, Research Center, Via Fiorentina 1, Siena I 53100, Italy
    World J Gastroenterol 13:349-54. 2007
    ..To investigate whether red wine and green tea could exert anti-H pylori or anti-VacA activity in vivo in a mouse model of experimental infection...
  19. ncbi Influenza vaccine immunology
    Philip R Dormitzer
    Novartis Vaccines and Diagnostics, Siena, Italy
    Immunol Rev 239:167-77. 2011
    ..The MF59 adjuvant broadens the distribution of B-cell epitopes recognized on HA and NA following immunization...
  20. ncbi Helicobacter pylori induces activation of human peripheral γδ+ T lymphocytes
    Benedetta Romi
    Novartis Vaccines and Diagnostics Research Center, Siena, Italy
    PLoS ONE 6:e19324. 2011
    ..pylori can directly interact with T cells and modulate the response of γδ+ T cells, thereby favouring an inflammatory environment which can contribute to the chronic persistence of the bacteria and eventually to the gastric pathology...
  21. ncbi Inflammation, immunity and vaccines for Helicobacter pylori
    Giuseppe Del Giudice
    Research Center, Chiron Vaccines, Siena, Italy
    Helicobacter 9:23-8. 2004
    ..Novel insights on the regulatory role of H. pylori on the adaptive T-cell response and on its consequences for the persistence of the infection and for the development of vaccines are discussed...
  22. ncbi Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles
    B C Baudner
    IRIS Research Center, Chiron SpA, 53100 Siena, Italy
    Infect Immun 70:4785-90. 2002
    ..These data strongly support the feasibility of development of intranasal vaccines with an enhanced protective efficacy against meningococci and possibly against other encapsulated bacteria...
  23. ncbi Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants
    M Pizza
    IRIS, Chiron S p A, Via Fiorentina 1, 53100, Siena, Italy
    Vaccine 19:2534-41. 2001
    ..g. tetanus, Helicobacter pylori, pertussis, pneumococci, influenza, etc). In conclusion, these LTK63 and LTR72 mutants are safe adjuvants to enhance the immunogenicity of vaccines at the mucosal level, and will be tested soon in humans...
  24. ncbi Effect of heparin binding on Helicobacter pylori resistance to serum
    J Daniel Dubreuil
    IRIS Research Center, Chiron Srl, Via Fiorentina 1, 53100 Siena, Italy
    J Med Microbiol 53:9-12. 2004
    ..In vivo, the process of heparin binding could possibly result in facilitated colonization due to a higher survival rate...
  25. ncbi The quest for a vaccine against Helicobacter pylori: how to move from mouse to man?
    Paolo Ruggiero
    IRIS Research Center, Chiron Srl, Via Fiorentina 1, 53100 Siena, Italy
    Microbes Infect 5:749-56. 2003
    ..These studies are also needed for deciphering those aspects of the effector immune responses that correlate with protection against H. pylori infection and disease...
  26. ncbi Polyphenols reduce gastritis induced by Helicobacter pylori infection or VacA toxin administration in mice
    P Ruggiero
    Chiron s r l, Research Center, Via Fiorentina 1, I 53100 Siena, Italy
    Antimicrob Agents Chemother 50:2550-2. 2006
    ..We show that polyphenol administration to mice experimentally infected by H. pylori or treated with VacA toxin can limit gastric epithelium damage, an effect that may be linked to VacA inhibition...
  27. ncbi Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza
    Giuseppe Del Giudice
    Novartis Vaccines and Diagnostics, Siena, Italy
    Expert Opin Biol Ther 13:121-35. 2013
    ....
  28. ncbi What are the limits of adjuvanticity?
    G Del Giudice
    IRIS Research Center, Chiron SpA, Via Fiorentina 1, 53100, Siena, Italy
    Vaccine 20:S38-41. 2001
    ..Tailoring of new adjuvants for the development of vaccines with improved immunogenicity/efficacy and reduced reactogenicity will represent one of the major challenges of the ongoing vaccine-oriented research...
  29. ncbi MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile
    Audino Podda
    Chiron Vaccines Clinical Research and Medical Affairs, Siena, Italy
    Expert Rev Vaccines 2:197-203. 2003
    ..MF59 has been the first adjuvant to be licensed for human use after alum and, as part of an enhanced influenza vaccine for the elderly, is now available in the marketplace of several countries worldwide...
  30. ncbi Molecular approaches for safer and stronger vaccines
    G Del Giudice
    IRIS Research Center, Chiron SpA, Siena
    Schweiz Med Wochenschr 129:1744-8. 1999
    ..These results demonstrate that a rational molecular approach to the development of safer and stronger vaccines is feasible...
  31. ncbi Genetically derived toxoids for use as vaccines and adjuvants
    G Del Giudice
    IRIS Research Center, Chiron SpA, Via Fiorentina 1, 53100, Siena, Italy
    Vaccine 17:S44-52. 1999
    ..These successful results show that rational design of stronger and safer vaccines is feasible...
  32. ncbi Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines
    F Falugi
    Chiron Research Center, Siena, Italy
    Eur J Immunol 31:3816-24. 2001
    ..The data indicate that rationally designed recombinant polyepitope proteins represent excellent candidates for the development and clinical testing of new conjugate vaccines...